Skip to main content
Premium Trial:

Request an Annual Quote

Abbott, Celera Dx's PCR-Based Hepatitis B Assay Wins CE Mark

NEW YORK (GenomeWeb News) — European Union regulators have cleared an Abbott assay that uses real-time PCR to monitor hepatitis B viral loads, Abbott and partner Celera Diagnostics said yesterday.
 
The certification allows the companies to market the test in the EU. The test runs on Abbott’s m2000 instrument, which uses PCR technology made by Applied Biosystems.
 
The m2000 also runs PCR tests for HIV-1, hepatitis C, chlamydia, and a combination test for chlamydia or gonorrhea.
 
Abbott and Celera Diagnostics received a CE Mark in 2005 for tests that monitor hepatitis C and HIV-1. The HIV-1 assay was also cleared by the US Food and Drug Administration in May.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.